KCT0007251已完成未知
A Multi-Center, Prospective, Randomized, Double-Blind, Active-Controlled, Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Fexuprazan in Patients with Laryngopharyngeal Reflux Disease
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. In visit 1, Age = 19
- •2. In visit 1, Symptoms of LPRD = 1 month
- •3. In visit 1, Patients with sore throat reflux
- •4. In visit 1, RSI = 13
- •5. In visit 1, RFS = 7
- •6. In visit 1, Patients who understand given information and write questionnaire
- •7. In visit 1, Those who voluntarily decide to participate in this clinical trial and give written consent
排除标准
- •[Past medical history]
- •1. Based on Visit 1, A person who has a history of malignant tumors within 5 years, (except Pharyngeal cancer, esophageal cancer, stomach cancer. but Malignant tumors can be participated if more than 5 years have elapsed without recurrence after being diagnosed with complete recovery.
- •2. Based on Visit 1, A person who has had a bronchial intubation within the last 3 months.
- •3. A person who has had radiation therapy in the neck area
- •4. Those who have undergone gastric acid suppression surgery or gastric and esophageal surgery (except simple perforation surgery, appendectomy, and benign tumor resection using an endoscope)
- •5. Those who have rare genetic problems such as fructose intolerance, poor absorption of glucose-galactose, or sucrose-isomaltase deficiency.
- •6. A person who has a history of overreacting of investigator product or same drugs (P-CAB, benzimidazole)
- •[Current medical history]
- •7. Those with diseases in the liver, kidney, cardiovascular system, respiratory system, internal branch system, and central nervous system that can affect the interpretation of clinical trial results under the judgment of the tester.
- •8. Patients with clinically significant psychiatric disorders
- •9. Those who have upper respiratory tract infections and allergies.
- •10. A person who has viral or bacterial laryngopharyngitis
- •11. Those who have gastrointestinal diseases as below.
- •A. Those who have been diagnosed with erosive gastroesophageal reflux disease or have the main symptoms of erosive gastroesophageal reflux disease (chest fever and/or reflux symptoms of body or bitter water flowing into the mouth).
- •B. People with esophageal diseases such as erosive esophagitis, esophageal stenosis, Barrett'sesophagus, and esophageal varicose veins.
- •C. People with peptic ulcers and gastrointestinal bleeding.
- •D. Those with Zollinger-Ellison syndrome, inflammatory diseases (cron disease or ulcerative colitis, etc.).
- •[Drug administration and treatment]
- •13.Based on Visit 1, those who are or are scheduled to take drugs related to the treatment (H2 receptor antagonists, prostaglandin drugs, gastric mucosal protectors, gastrointestinal motility promoters) of gastroesophageal reflux disease within the last two weeks.
- •14. A person who has administered the following drugs or needs continuous administration during the clinical trial period.
- •? Gastric acid Inhibitor : H2 receptor antagonists, proton pump inhibitors (PPI), potassium-competitive gastric acid secretion inhibitors (P-CAB), and anti-gasstrin agents
- •? Gastric mucosal protector
- •? Gastrointestinal motility booster.
- •? Digestive machine Jin Economy
- •? Choline (however, local administration is allowed)
- •? Glucocorticosteroid (however, local administration is allowed)
- •Forbidden during clinical trial.
- •? Nonsteroidal anti-inflammatory analgesics.
- •? Antiviral drugs such as lilpivirin, Atazanavir, and Nelpinavir.
- •? Antipsychotics, antidepressants, anti-anxiety drugs.
- •? Antithrombotic (anticoagulant or antiplatelet)
- •15. A person who participated in another clinical trial within 4 weeks of Visit 1 and was administered or applied to a clinical trial drug or medical device at least once.
- •[Laboratory test]
- •16. Among the blood chemistry test results of Visit 1, who meets the following criteria.
- •alanine aminotransferase (ALT)= ULN (Upper limit of normal) X2
- •aspartate aminotransferase (AST)
- •alkaline phosphatase (ALP)
- •gamma-glutamyl transferase (G
研究者
相似试验
已完成
3 期
A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA * Intervention Trial)heart and vessel disease1001108210047066cardiovascular diseaseNL-OMON46966Amarin Pharma Inc.1,700
进行中（未招募）
1 期
ot applicableCardiovascular Disease or at High Risk for Cardiovascular DiseaseMedDRA version: 20.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 100000004861EUCTR2011-004726-10-NLAmarin Pharma Inc.7,990
招募中
3 期
A study to determine the effectiveness and safety of AMR101 in reducing the risk of cardiovascular events (e.g. stroke, heart attack, unstable angina) in patients with high triglyceride levels and who are on statin treatments.CTRI/2012/05/002653Amarin Pharma Inc7,990
进行中（未招募）
1 期
ot applicableEUCTR2011-004726-10-PLAmarin Pharma Inc.7,990
已完成
不适用
This is a clinical trial to compare clinical efficacy, safety and tolerability of generic Diclofenac Sodium Topical Gel 1%, with Voltaren® Gel (a Diclofenac Sodium Topical Gel 1%) and Vehicle of Diclofenac Sodium Topical Gel 1% in subjects with osteoarthritis(degenerative joint disease) of the kneeCTRI/2015/09/006149Cipla Limited990